Disulfiram, an Anti-alcoholic Drug, Targets Macrophages and Attenuates Acute Rejection in Rat Lung Allografts
Transplant International · 2024
DOI: 10.3389/ti.2024.12556 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant International, 2024. Verfasst von Nobuyuki Yoshiyasu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Hauptthemen laut MEDLINE: Lung Transplantation, Graft Rejection, Disulfiram, Rats, Inbred Lew. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Macrophages contribute to post-transplant lung rejection. Disulfiram (DSF), an anti-alcoholic drug, has an anti-inflammatory effect and regulates macrophage chemotactic activity. Here, we investigated DSF efficacy in suppressing acute rejection post-lung transplantation. Male Lewis rats (280–300 g) received orthotopic left lung transplants from Fisher 344 rats (minor histocompatibility antigen-mismatched transplantation). DSF (0.75 mg/h) monotherapy or co-solvent only (50% hydroxypropyl-β-cyclodextrin) as control was subcutaneously administered for 7 days (n = 10/group). No post-transplant immunosuppressant was administered. Grades of acute rejection, infiltration of immune cells positive for CD68, CD3, or CD79a, and gene expression of monocyte chemoattractant protein and pro-inflammatory cytokines in the grafts were assessed 7 days post-transplantation. The DSF-treated group had significantly milder lymphocytic bronchiolitis than the control group. The infiltration levels of CD68 + or CD3 + cells to the peribronchial area were significantly lower in the DSF than in the control groups. The normalized expression of chemokine ligand 2 and interleukin-6 mRNA in allografts was lower in the DSF than in the control groups. Validation assay revealed interleukin-6 expression to be significantly lower in the DSF than in the control groups. DSF can alleviate acute rejection post-lung transplantation by reducing macrophage accumulation around peripheral bronchi and suppressing pro-inflammatory cytokine expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Respiratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
- Department of Thoracic Surgery, The University of Tokyo Hospital, Tokyo, Japan.
- Department of Respiratory Medicine, The University of Tokyo Hospital, Tokyo, Japan.
- Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan.
- Division of Molecular Regulation of Inflammatory and Immune Diseases, Research Institute for Biomedical Sciences (RIBS), Tokyo University of Science, Chiba, Japan.
Zitieren
APA
Yoshiyasu, N., Matsuki, R., Sato, M., Urushiyama, H., Toda, E., Terasaki, Y., Suzuki, M., Shinozaki-Ushiku, A., Terashima, Y., & Nakajima, J. (2024). Disulfiram, an Anti-alcoholic Drug, Targets Macrophages and Attenuates Acute Rejection in Rat Lung Allografts. Transplant International. https://doi.org/10.3389/ti.2024.12556
Vancouver
Yoshiyasu N, Matsuki R, Sato M, Urushiyama H, Toda E, Terasaki Y, et al. Disulfiram, an Anti-alcoholic Drug, Targets Macrophages and Attenuates Acute Rejection in Rat Lung Allografts. Transplant International. 2024. doi:10.3389/ti.2024.12556
BibTeX
@article{Yoshiyasu2024,
author = {Yoshiyasu, Nobuyuki and Matsuki, Rei and Sato, Masaaki and Urushiyama, Hirokazu and Toda, Etsuko and Terasaki, Yasuhiro and Suzuki, Masaki and Shinozaki-Ushiku, Aya and Terashima, Yuya and Nakajima, Jun},
title = {Disulfiram, an Anti-alcoholic Drug, Targets Macrophages and Attenuates Acute Rejection in Rat Lung Allografts},
journal = {Transplant International},
year = {2024},
doi = {10.3389/ti.2024.12556}
}
EUVIMED